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Abstract 
 
Asthma in Scotland: prescribing trends since the National Review of Asthma Deaths 
(NRAD) 
 
Purpose:  Asthma remains prevalent worldwide with implications for morbidity and 
mortality. In Scotland, 1 in 14 people are currently being treated for asthma. Asthma burden 
prompted the creation of the National Review of Asthma Deaths (NRAD), which identified 
contributing factors. Since the NRAD, guidelines have changed and therapeutic indicators 
have been developed with an increased emphasis on controller medications. Few 
publications describe how the NRAD study affected prescribing and if inequalities among 
the asthmatic population exist. This study aimed to determine whether patients were 
receiving appropriate treatment according to therapeutic guidelines and how prescribing 
has changed over time.  
 
Methods:   Scotland’s Prescribing Information System (PIS) was used to gain access to 
population-based outpatient prescription drug claims for Short-Acting Beta-Agonists 
(SABAs), Long-Acting Beta-Agonists (LABAs), and Inhaled Corticosteroids (ICSs), to 
create a cohort of asthma patients aged 0-39. All ethical approvals necessary were obtained 
according to the National Health System (NHS) of Scotland’s specified guidelines for de-
identified patient data. Patients were stratified by age, gender, socioeconomic status (SES), 
and medication type to compare rates of prescribing for different populations. Using 
NRAD and the national therapeutic indicators as metrics, the data was analyzed to assess 
changes over time. The primary outcomes included whether there was a difference in 
asthma prescribing from 2014 to 2018; if there were any significant demographics 
differences among those with uncontrolled asthma; and whether drug claims were 
consistent with asthma guidelines. 
 
Results:  A total of 222,637 patients were analyzed from 2014 and 205,758 from 2018. In 
2018, 7.42% of those received more than 12 SABAs per year, 20.77% received more than 
6, and 42.39% received more than 3, only slightly lower than in 2014 (8.85%, 21.83%, 
43.73% respectively). For the most recent year that data was available (2018) further 
analyses were completed. Prevalence of receiving more than 12 SABAs was found to be 
higher among patients who were male, as well as patients aged 30-39, or those with lower 
SES. Use of greater than 12 SABAs varied almost two-fold between the populations with 
the highest and lowest SES (lowest SES – 9.0%; highest SES – 4.6%). When looking at 
measures related to the therapeutic guidelines, only 89% of patients receiving more than 
12 SABAs had received an ICS; of those, only 41% received an adequate amount of ICS 
medications over the year. 
 
Conclusion: Prescribing practices have changed slowly since the NRAD study was 
published. When looking at the therapeutic guidelines, prescription drug claims show a 
disconnect with the recommendations. There appears to remain an over-reliance on reliever 
medications with a deficit in controller medications. This study shows that a large Scottish 
asthmatic population remains at increased risk of poor outcomes. More studies are needed 
to further research hospitalization, morbidity, and mortality rates as well as cost analyses, 
to further characterize change over time and whether new measures are needed to improve 
outcomes. 
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Introduction 
Asthma is a chronic inflammatory disease of the respiratory system that can result 
in dyspnea, wheezing, cough, and chest tightness due to airway obstruction [1]. The 
underlying pathophysiology and resulting airway obstruction can lead to potentially severe 
respiratory symptoms, limitations of activity, and asthma attacks (exacerbations) that can 
require urgent healthcare attention and can even be fatal [2]. Poorly controlled asthma has 
been linked to increases in the risk of poor quality of life, increased asthma attacks, 
increased healthcare expenditures, and even premature death [3,4]. 
Asthma remains a prevalent issue worldwide, with approximately 300 million 
people estimated to have asthma and an estimated 100 million more to be affected by the 
year 2025 [5,6]. While asthma-related hospitalizations and deaths have been shown to 
decrease in most countries [7], the global burden for patients with exacerbations and day-
to-day symptoms has increased by almost 30% in the past 20 years [8]. In addition, the 
World Health Organization (WHO) has estimated that 15 million disability-adjusted life 
years are lost, and 250,000 asthma deaths are reported annually worldwide [9]. In the 
United Kingdom (UK), 5.4 million people are currently receiving treatment for asthma 
[10]. More concerning is that the UK had a 20% increase in the rate of asthma attack deaths 
over the five-year period from 2010 to 2015, culminating in 1434 people dying of an 
asthma attack in 2015 [11]. This spike prompted the National Review of Asthma Deaths 
(NRAD) in which the asthma deaths were reviewed to see if any common preventable 
mistakes might have precipitated the deaths.  
The factors the NRAD looked at included: the use of National Health System 
(NHS) services, medical & professional care, prescribing & medicines use, patient factors, 
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and perception of risk or poor control [12]. The findings of the prescribing and medicines 
use component represents the basis for this study. Common asthma medications classes 
include short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and 
inhaled corticosteroids (ICSs). These medication classes can be categorized into reliever 
(SABAs and LABAs) or preventer medications (ICSs). Reliever medications only relieve 
the symptoms through dilating the airways allowing more air to pass through. In contrast, 
preventer medications help prevent the underlying cause of inflammation, allowing 
reversal of the pathophysiological changes that occur due to asthma [13]. Among the 
findings of NRAD in prescribing and medicines use was that there was evidence of 
excessive prescribing of reliever medications (SABAs), under-prescribing of preventer 
medications (ICSs), and evidence of inappropriate prescribing of LABA inhalers [12]. In 
addition to this, the NRAD found that 65% of the asthma deaths reviewed had a preventable 
factor [12]. These results showed that asthma treatment can be vastly improved in the UK 
and that there remains a population at-risk for fatal consequences despite advances in 
asthma treatment over the years.  
In response to the NRAD, NHS Scotland issued National Therapeutic Indicators 
(NTI) aimed at medication findings of the study. NTIs are used to alert healthcare 
practitioners of a potential marker for poor disease state management that can be tracked 
over time. These NTIs represent a way to use prescription data to inform and monitor 
markers for potential poor economic outcomes, reduced healthcare outcomes, including 
impacts of morbidity and mortality, as well to track prescribing patterns in various regions 
of Scotland [14]. An example of an asthma NTI issued after the NRAD relevant to this 
study is, “More than 12 SABAs per annum as a percentage of all people prescribed SABAs 
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[15].” In addition to NTIs, disease-specific guidelines exist for numerous healthcare topics. 
For asthma, the main guidelines of reference in Scotland are the Scottish Intercollegiate 
Guideline Network/ British Thoracic Society (SIGN/BTS), but there also exists the 
National Institute for Health and Care Excellence (NICE), and the Global Initiative for 
Asthma (GINA). There is one specific change in the SIGN/BTS guidelines that is of 
interest to this study. This change is the add on of ICS medications as first-line options in 
the treatment of asthma. When the NRAD was published in 2014, the guidelines stated to 
start SABA medication as first-line then if the asthma is not controlled add on ICS [Figure 
1, appendix]. In 2016 an update was released, and the main treatment change was 
considering add-on of ICS as soon as someone is diagnosed with asthma [Figure 2, 
appendix]. This change could result in ICS medications being started earlier in the 
treatment of asthma and could have implications on asthma outcomes. 
When looking at the history of medication usage for asthma, there are many 
instances of changes to prescribing guidelines as more information and new medications 
are introduced. Medications have played a direct role in the decrease in mortality in the last 
50 years but can also be linked to spikes in mortality during specific time frames [12,16,17]. 
These publications help to show the changes over time of asthma prescribing and give a 
snapshot of the implications that asthma medications have on outcomes. The interplay of 
evidence-based medicine and uptake into practice is a relevant interest for the data-driven 
and connected world. It is suggested that it sometimes takes more than a decade to 
implement research results in clinical practice and that it is often challenging to sustain 
innovations over time [18]. With all of the available resources and guidelines specific to 
asthma, it is understandably a daunting task for healthcare providers to remain up to date 
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with this complex disease that represents just one of the numerous chronic diseases. It is 
of interest to understand and have methods to influence prescribing habits to coincide with 
the most recent information. 
Based upon the NRAD, Scotland’s NTIs, and changes in asthma guidelines, there 
is a lot of evidence for how asthma should be treated and the implications on health for 
asthma that is not managed adequately. While research forms the basis for these guidelines, 
there are a multitude of other factors that can influence whether or not the health outcomes 
reflect treatment under ideal situations. Some of these factors that affect asthma outcomes 
include adherence, proper inhaler technique, prescribing that matches the latest guidelines, 
and socioeconomic factors [19,20,21,22]. Few publications describe how the NRAD study 
affected prescribing in Scotland and if inequalities exist in their asthmatic populations. This 
study aimed to determine whether patients were receiving appropriate treatment according 
to therapeutic guidelines and how asthma medication prescribing has changed over time. 
NHS Scotland data was used to see the effects over time, utilizing the Prescribing 
Information System (PIS) dataset. The objectives of this study include: determine if there 
has been a change in asthma prescribing since the NRAD study was published using NRAD 
and NTI measures; determine if there is a difference for asthma medication prescribing 
among age, gender, and socioeconomic status; determine if the SIGN/BTS guidelines are 
being followed in those receiving medications used to treat asthma. 
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Methods 
 
Scotland’s Prescribing Information System (PIS) was used as the data source for 
this study. PIS is the definitive data source for prescribing information of all items 
dispensed in the outpatient setting in Scotland. The data is maintained and used by the 
Information Services Division (ISD) of the NHS National Services Scotland (NSS). The 
data includes unique patient identifier (UPI), patient demographics, prescriber and 
dispenser details, geographical and deprivation details, as well as costs and drug 
information. The data have been collected since 1993 and gets updated monthly. The UPI 
has been attached to the prescribing data since 2009 and allows for linking of prescription 
events to an individual as well as linking of prescription events for a population based on 
patient-specific information and demographics. The main limitation of PIS is that there are 
no diagnosis codes attached to the dispensing information. As a result, assumptions were 
made regarding indication, the severity of asthma, and adherence. The study population is 
only those in Scotland that have gotten a SABA medication. Because SABAs can be used 
for other ailments besides asthma, a quantity filter was added to help differentiate between 
short-term SABA use for ailments like pneumonia and long-term SABA use for asthma. 
The quantity filter stratified patients into those receiving greater than 3, 6, and 12 SABAs. 
These quantity filters are not mutually exclusive; a patient receiving 13 SABAs in the year 
would be included in patient counts of each SABA quantity category (>3, >6, and >12 
SABAs). These quantity filters were selected because they have been used in previous 
studies, including the NRAD [12]. There is also overlap with asthma and COPD. To 
account for this age boundaries and age strata were also used to lessen the amount of COPD 
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patients among the study population and to be able to see how SABA use changed with 
age. COPD is a chronic disease that becomes apparent after 40 or 50 years of age [23]. 
Limiting the study population of asthma to patients aged 39 or younger allows less overlap 
between asthma and COPD.  
Another assumption that was made was the definition of uncontrolled asthma. For 
this, it is assumed that patients in higher SABA quantity strata had asthma that was less 
well-controlled than patients in the lower SABA quantity strata. In the context of outside 
literature definition of asthma control, the SIGN/BTS guidelines have a practical definition. 
It defines uncontrolled asthma in need of additional therapy as the use of 3 doses or more 
of a SABA per week [24]. To put this into context, in 2018, the most dispensed SABA is 
one that contains 200 doses per canister. This medication accounted for approximately 78% 
of SABA dispensing. By the SIGN/BTS definition for uncontrolled asthma, this would 
mean that if they had controlled asthma, then they would only be using a max of 2 doses 
per week. With the most commonly dispensed inhaler, it would last them 100 weeks, 
meaning they would only need one inhaler per year. While some circumstances can result 
in an asthmatic needing inhalers on-hand in different locations that are not actively being 
used, the quantity filters can help to gauge the control of a patient’s asthma. The last 
assumption is that adherence is not a confounder for potential differences in the 2014 and 
2018 data. It is assumed that adherence is constant between the years so that inferences can 
be made about prescribing trends. This is further discussed in the discussion section and 
represents an area to investigate in follow-up studies. The result of these assumptions can 
over-estimate the asthmatic population, but the filters allow a more accurate representation 
of those with asthma and allow a reference point to try and gauge poorly controlled asthma. 
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When factoring in a comparison between two years, this can also allow for a good overview 
of how asthma prescribing has changed. 
Trial Design 
The study was conducted as a cross-sectional study using PIS data in the years 2014 
and 2018. The two years were used to assess changes over time in prescribing trends to see 
the effect of guideline changes, NTI, and the NRAD. Then the year 2018 data was 
expanded to look more in-depth at the demographics of the Scotland asthma population to 
assess risk-factors for poorly controlled asthma in the most recent complete years data. The 
program SAP BusinessObjects Business Intelligence 4.1 was used to retrieve data. This 
program was used to query the data and pull data specific to set parameters. While the year 
2018 was used because it was the most recent available, the year 2014 was used because 
this was the year that the NRAD was published and the baseline/ reference population data 
for the study. The data was retrieved on June and July 2019. 
The queries were designed to make a study population that included all of those 
that received a SABA medication as defined by the British National Formulary (BNF) in 
2014 and 2018 that were aged 0-39. This population was then filtered using age strata (0-
9, 10-19, 20-29, 30-39), approved drug name, drug formulation, paid calendar year, BNF 
item description, medications by paid quantity (SABA, LABA, ICS, and combo inhalers), 
Scottish Index of Multiple Deprivation (SIMD), and gender description in various 
combinations to test the objectives. These filters were selected and used as categorical data 
as opposed to continuous data to allow more insight into which part of the Scotland 
population is most at-risk for poor outcomes. This choice was assumed to give more 
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information that can be used for follow-up studies or interventions, than if continuous 
variables were utilized.  
For objective 1, the two years were compared to see how asthma prescribing has 
changed over time. This compared the prescribing of SABA, LABA, and ICS between the 
two years. Patient counts were conducted for the total number of patients that received a 
SABA, patient count receiving >3, >6, and >12 SABAs; patient count of any ICS, ≥12 ICS, 
and >14 ICS; patient count receiving any LABA, and LABA monotherapy. The patient 
counts were then changed into percent, and rates, utilizing rate per 1000 patients. Relative 
risk was then calculated between 2014 and 2018, with the year 2014 being used as a 
baseline to see if there were changes over time. For objective 2, the data from 2018 was 
filtered by age, gender, and socioeconomic status to look to see if there were any 
demographic differences for those utilizing SABA inhalers or if there was a difference in 
demographics for those with poorly controlled asthma. Rates were compared in the >3, >6, 
and >12 SABA groups between age, gender, and SIMD. Relative risk was used to calculate 
differences in the groups, with the entire population being used as the reference population, 
with figures and tables being made to show the results. For gender, the relative risk 
calculation utilized the comparison between males and females, with females being the 
baseline. For age, the relative risk was compared between age strata with the entire 
population as the reference population to assess which age groups had increased risk of 
uncontrolled asthma. For socioeconomic status, the SIMD category was used to find the 
relative risk between each category with the entire population as the reference population 
to see if there were any differences in socioeconomic status contributing to asthma burden. 
SIMD is a numerical ranking of socioeconomic status. It separates the population into equal 
	 14	
categories from 1 to 5, with 1 being the most deprived and 5 being the least deprived. This 
means that 1 represents the lowest socioeconomic status, while 5 represents the highest 
socioeconomic status. Objective 3 looked at asthma prescribing in 2014 and 2018 and 
compared the claims to the SIGN/BTS guidelines to assess changes over time. This looked 
at the co-prescribing of SABA and ICS prescriptions and broke it down to percent of >3, 
>6, >12 SABAs, Any ICS, and ICS ≥12. SABA and ICS are the main medications used to 
treat asthma, and when looking at the SIGN/BTS guidelines, they now represent first-line 
treatment (Figure 2, appendix). The treatment guidelines become more complicated after 
the first two steps and become more complicated to test. Relative risks were then calculated 
to see if there were changes over time in ICS prescribing, utilizing 2014 as the baseline 
data. Those receiving SABA and ICS inhalers were further broken down into the percent 
receiving ≥12 ICS to assess if there were an adequate number of ICS inhalers prescribed. 
This again utilized 2014 as the baseline data for the relative risk calculations. The data 
extraction and figures were made with BusinessObjects. The raw data was also exported 
into Microsoft Excel where the calculations, including relative risk, were made. 
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Results 
A total of 222,637 patients received a SABA medication in 2014 and 205,758 patients in 
2018. These numbers represent the total study population utilized. Table 1 shows the 
patient counts for those receiving SABAs, LABAs, and ICSs.  
Table 1 – Patient counts 
 2014 2018 
Total Population aged 0-39 2,545,486 2,592,524 
Any SABA (study 
population) 
222,637 205,758 
>3 SABA 97,363 87,227 
>6 SABA 48,602 42,732 
>12 SABA 19,705 15,263 
Any ICS 126,136 122,763 
ICS >/= 12 12,579 11,340 
ICS >14 5,443 4,541 
Any LABA 42,518 44,920 
Single-component LABA 3,375 1,345 
Any LABA and no ICS 231 171 
 
When looking at the total population aged 0-39 in Scotland for the two years (2,592,524 in 
2018 and 2,545,486 in 2014), 7.9% of the population in 2018 and 8.7% of the population 
in 2014 received a SABA. Of those receiving a SABA in 2018, 7.42% received >12 SABAs 
per year, 20.77% received >6 SABAs per year, and 42.39% received >3 SABAs per year. 
In 2014, those numbers were 8.85%, 21.83%, and 43.73% respectively. To show the 
differences, the relative risk was calculated and put into a table listing the relative change 
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along with the absolute change. The relative risk calculations used 2014 as a baseline, and 
therefore it is the reference population. The results of objective 1 are shown in Table 2.  
Table 2 – Relative and absolute change between years 
 2014  2018 Relative Risk (CI) Relative 
change 
Absolute 
change 
>3 SABAs 43.73% 42.39% 0.97 (0.96 – 0.98 P 
<0.001) 
3.06% 
decrease 
1.43% 
decrease 
>6 SABAs 21.83% 20.77% 0.95 (0.94 – 0.96 P 
<0.001) 
4.87% 
decrease 
1.06% 
decrease 
>12 SABAs 8.85% 7.42% 0.84 (0.82 – 0.86 P 
<0.001) 
16.19% 
decrease 
1.34% 
decrease 
Any ICS 56.66% 59.66% 1.05 (1.04 – 1.06 P 
<0.001) 
5.31% 
increase 
3% 
increase 
ICS >/= 12 5.65% 5.51% 0.97 (0.95 – 0.99 P 
=0.048) 
2.5% 
decrease 
0.14% 
decrease 
>14 ICS 2.44% 2.21% 0.90 (0.87 – 0.94 P 
<0.001) 
9.73% 
decrease 
0.23% 
decrease 
Any LABA 19.09% 21.83% 1.14 (1.13 – 1.16 P 
<0.001) 
14% 
increase 
2.74% 
increase 
Single 
component 
LABA 
1.52% 0.65% 0.43 (0.40 – 0.46 P 
<0.001) 
57% 
decrease 
0.87% 
decrease 
Any LABA, 
no ICS 
0.10% 0.08% 0.80 (0.66 – 0.98 P 
=0.028) 
19% 
decrease 
0.02% 
decrease 
 
For objective 2, only the year 2018 was examined. Utilizing the amount of SABA 
inhalers prescribed to gauge asthma control, SABAs received per year were analyzed in 
>12, >6, and >3 inhaler groups and compared between demographics. The rates of these 
various SABA quantities were graphed with gender, age strata, and SIMD. On the y-axis 
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of the histograms is the rate of those receiving >3, >6, or >12 SABA inhalers out of all 
those receiving at least one SABA inhaler per 1000. On the x-axis, it is broken down into 
the age bands, gender, and SIMD. The blue bars represent the females, and the green bars 
represent the males. The numbers 1-5 represent the SIMD or socioeconomic status, with 
1 representing the lowest socioeconomic status and 5 representing the highest 
socioeconomic status. The age bands are ordered from left to right of the 0-9, 10-19, 20-
29, and 30-39 age bands. This gives a broad snapshot of every demographic component 
that was measured in objective 2. These are shown in figures 3, 4, and 5.  
 
Figure 3 – Rate of >3 SABA per 1000 stratified by age, SIMD, and gender  
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Figure 4 – Rate of >6 SABA per 1000 stratified by age, SIMD, and gender 
 
 
Figure 5 – Rate of >12 SABA per 1000 stratified by age, SIMD, and gender 
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Age 
When looking at the figures, figure 3 shows the rate of >3 SABAs is highest in the age 
band 0-9, followed by 30-39. When looking at figure 4, the rate of >6 SABAs the figure 
levels off between age strata, but more differences can be seen between gender and SIMD. 
Lastly, figure 5, the >12 SABAs figure, shows that the relative risk becomes greater for the 
age band 30-39. To illustrate these figures numerically, the relative risk was calculated in 
>3, >6, and >12 SABA groups between the age strata. These age results are tabulated and 
shown in table 3. 
Table 3 – Age relative risk stratified by SABA quantity 
 0-9 10-19 20-29 30-39 
>3 SABAs  1.45 (1.43 – 1.46 
P<0.001)  
0.78 (0.77 – 0.79 
P<0.001)  
0.84 (0.83 – 0.85 
P<0.0001)  
1.01 (0.99 – 1.02 
P=0.075) 
>6 SABAs 1.14 (1.12 – 1.16 
P<0.0001)  
0.70 (0.70 – 0.71 
P<0.0001)  
0.96 (0.94 – 0.98 
P<0.001) 
1.21 (1.19 – 1.24 
P<0.0001)  
>12 SABAs 0.99 (0.95 – 1.02 
P=0.49)  
 0.62 (0.60 – 0.65 
P<0.0001) 
1.05 (1.02 – 1.09 
P=0.0034) 
1.34 (1.30 – 1.39 
P<0.0001)  
 
Gender 
When looking at gender, there is an increased relative risk for males when compared to 
females. There is a 30% increased risk of receiving >12 SABAs, 25% increased risk for >6 
SABAs, and 21% increased risk for >3 SABAs. The results are shown in table 4. 
Table 4 – Gender relative risk stratified by SABA quantity 
 Relative Risk (CI) P 
>12 SABAs 1.30 (1.26, 1.34)  <0.001 
>6 SABAs 1.25 (1.22, 1.27) <0.001 
>3 SABAs  1.21 (1.20, 1.22)  <0.001 
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SIMD 
When looking at SIMD, there is an apparent higher relative risk attributed to the lowest 
socioeconomic status groups, and as the socioeconomic status category decreases, the 
relative risk increases. This is shown in figures 6, 7, 8.  
Figures 6 – SIMD relative risk in >3 SABA group 
 
Figure 7 – SIMD relative risk in >6 SABA inhaler group 
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Figure 8 – SIMD relative risk in >12 SABA group 
 
For objective 3, the SIGN/BTS guidelines were used. The co-prescribing of SABA and 
ICS represents the optimum treatment, with both a reliever and preventer medication. The 
year 2014 and 2018 were compared to see the changes over time. In 2018, 89% of those 
receiving >12 SABAs had received an ICS. When looking at the number of ICS inhalers 
received in those receiving >12 SABAs and at least 1 ICS, 41% received the recommended 
12 ICS inhalers. Table 5 shows the comparison between years in the co-prescribing of 
SABA and ICS. 
Table 5 – Co-prescribing of SABA and ICS 
  2014 2018 Relative Risk 
(CI) 
Relative 
Change  
Absolute 
Change 
>3 
SABA 
Any ICS 77.02% 78.62% 1.02 (1.01 – 1.03 
P<0.0001) 
2.07% 
increase 
1.6% 
increase 
Percent ICS ≥12 
of those with Any 
ICS 
15.88% 15.48% 0.98 (0.95 – 0.99 
P=0.0395) 
2.49% 
decrease 
0.4% 
decrease 
>6 
SABA 
Any ICS 84.88% 86.09& 1.01 (1.01 – 1.02 
P<0.0001) 
1.43% 
increase 
1.21% 
increase 
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Percent ICS ≥12 
of those with Any 
ICS 
25.64% 24.86% 0.97 (0.95 – 0.99 
P=0.0123) 
3.05% 
decrease 
0.78% 
decrease 
>12 
SABA 
Any ICS 87.96% 89.08% 1.01 (1.01 – 1.02 
P=0.0011) 
1.27% 
increase 
1.12% 
increase 
Percent ICS ≥12 
of those with Any 
ICS 
41.13% 41.39% 1.01 (0.98 – 1.03 
P=0.6415) 
0.64% 
increase 
0.26% 
increase 
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Discussion 
 
When looking at asthma medication prescribing, one can see that there are a good 
number of patients in Scotland that received a SABA medication. While this undoubtedly 
over-estimates the number of asthmatics in Scotland, when looking at reported incidences, 
comparisons can be made to see how much it overestimates. The incidence of asthma in 
Scotland is said to be 1 in 14 that are currently receiving treatment [10]. Utilizing 
population counts in the determined age strata showed the study population had an 
incidence of 1 in 11 receiving SABA claims in 2014 and 1 in 13 in 2018. This shows that 
while it may overestimate the number of asthmatics, it represents a study population that 
should encompass the asthma population in the age strata, with additional patients that 
utilize SABAs for other ailments.  
When comparing the 2014 and 2018 data, it shows the total 0-39 population 
increases between the years while the number of patients receiving a SABA medication 
decreases. This result is consistent throughout the filter quantity of SABA inhalers. When 
looking at relative risk, there is a relative decrease of patients receiving drug claims for 
SABAs, and this becomes greater as the filter for the number of SABA inhaler increases. 
The most substantial reduction in patient SABA claims occurs in the >12 SABA group. 
This reduction shows that there is a relative decrease of 16.19% compared to 2014. When 
thinking about the NTI and guideline changes, this is in line with them because there was 
an emphasis on patients receiving >12 SABAs after the NRAD data was published. It 
appears prescription drug claims for the asthmatics with the least controlled asthma, that 
are receiving the most SABAs, have had a greater reduction. This could be due to any one 
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of the changes mentioned previously, but the change is significant enough to show positive 
changes that have occurred after the NRAD. Although, when looking at the absolute 
change, there has been a small change of 1.34% between the years. This small absolute 
change likely indicates there is more room for improvement. When looking at the other 
measures, there is not as large of a decrease in both relative risk change and absolute risk 
change. This may show that the patients receiving the most inhalers are getting the most 
attention when it comes to the over-reliance of reliever medications. At the same time, it 
appears that there remains room for improvement in the other categories. The amount of 
room for improvement in the other categories needs additional review so that more 
definitive information with diagnosis codes can help dictate measures. Additionally, this 
data shows that there remain 15,263 patients that receive >12 SABAs, a risk for poor 
outcomes. 
The changes in ICS drug claims between the years shows a decrease in the number 
of patients with ICS claims in all three categories. When looking at relative risk, there is a 
9.73% decrease in patients receiving >14 ICS. This represents a cost-saving initiative for 
the NHS and does not relate to clinical outcomes. When looking at the clinical measures, 
there was an increase in the percentage of patients receiving any ICS inhaler. This equated 
to a 3% absolute increase (the largest absolute change in objective 1) and a 5.31% relative 
increase between the years. ICS inhalers have become more common due to the 
preventative nature of their mechanism. In the guidelines, they have become an option for 
first-line therapy. These relative and absolute increases coincide with the guideline changes 
and could show that more patients are being started on ICS inhalers. If the patient has 
asthma, then they have an indication for an ICS inhaler. When considering the amount of 
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ICS inhalers, a patient needs, you have to consider the mechanism of action. ICSs are a 
medication that a patient needs to take every day. Given that the NHS/BTS formulary has 
only ICS inhalers that contain 30-day supplies, one would expect asthmatics to need 12 
ICS inhalers per year if they are prescribed them. When looking at the data, there is a 2.5% 
relative decrease between years of patients receiving ≥ 12 ICS inhalers compared to 2014. 
This statistic alone is hard to analyze, but in objective 3, it looks more into this and assesses 
if those with uncontrolled asthma are adequately getting treated with goal-directed therapy. 
The big take-away from the ICS component of objective 1 is that those receiving SABA 
inhalers in 2018 are receiving ICS inhalers at a higher frequency than in 2014. While the 
frequency of those receiving ≥12 has decreased. 
LABA inhalers’ place in therapy is more convoluted than SABAs and ICSs. While 
SABA and ICS represent first-line therapy options, LABA inhalers represent therapy later 
in the sequential stepwise nature of the SIGN/BTS guidelines. Given previous studies’ 
results on the use of LABA as monotherapy [25], assessing if prescribing has changed is 
pertinent to ensuring optimum therapy. While the percentage of patients receiving any 
LABA has increased between the years, when breaking it down to single-component and 
monotherapy, LABA prescribing has decreased. The single-component LABA statistic 
represents something that could have a clinical difference. The NRAD showed that single-
component LABA was a risk factor for poorly controlled asthma. If a patient receives a 
prescription for a single-component LABA, they may only be using that inhaler regardless 
of other inhalers that have been prescribed to them. This increases the chance that an 
asthmatic is using LABA as monotherapy. Instead, NRAD and guidelines have moved 
towards prescribing LABAs that are included in combo inhalers [12]. That is LABA and 
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ICS in one inhaler. Combo inhalers can increase compliance to goal-directed medical 
therapy and decrease the chances that a patient uses LABA as monotherapy. Looking at 
the changes in monotherapy or single-component LABAs shows the greatest relative 
decrease in all medication categories. There was a 57% relative decrease in patients 
prescribed single-component LABAs between the years, a 19% relative decrease in any 
LABA without an ICS, and a 47% relative decrease in single-component LABA without 
an ICS. This represents a decrease in the prescribing of LABAs and a potential decrease in 
those at-risk for poor outcomes that coincide with LABA monotherapy. 
For objective 2, the year 2018 was used to assess demographic and socioeconomic 
status differences. SABA inhaler claims were the only medication examined and again 
under the assumption that the more inhaler claims, the less the asthma is controlled. When 
looking at the figures of the number of SABA inhalers with age strata, gender, and 
socioeconomic status, it gives a good insight into how prescribing differs between these 
various groups. The y-axis of figures 3, 4, and 5 show the rate of SABA inhalers per 1000 
patients. While the scale changes in each of the three figures, making it harder to compare, 
the rate in the various groups in the individual figures can be compared. In figure 3, the 
age band 0-9 has the highest rate of >3 SABAs, and there is not an easily visible difference 
between socioeconomic status among this age band. Then when looking at figure 4 (>6 
SABAs), the rate between age strata starts to level off. The differences between gender and 
socioeconomic status become more pronounced in this figure, as well. Figure 5 has the 
most noticeable differences between socioeconomic status and gender. Also worth noting 
is that the age band 30-39 now has the highest rate of those receiving >12 SABAs when 
compared to the other age strata.  
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As discussed previously, the 0-9 age band has the highest rate in >3 SABAs with 
45% increased relative risk of getting >3 SABAs compared to the other age strata. As the 
number of inhalers increases to the >6 SABAs and >12 SABAs groups, the relative risk 
decreases for the 0-9 age band. While in the age band 30-39, the relative risk increases as 
the number of SABA inhalers increases. In the >12 SABAs group, there is a 34% increased 
relative risk in the 30-39 group compared to the other age strata. These increases in rate in 
the oldest population group as the number of SABA inhalers increase may be due to 
behavioral health factors. This observation would coincide with previous data on smoking 
and asthma, showing that smoking increases the risk of asthma and asthma that is more 
difficult to control [26]. The takeaway from this portion of the data is that younger age 
individuals may be at greater risk of needing a SABA, but as age increases, so does the 
apparent rates of uncontrolled asthma and the need for large quantities of SABA inhalers. 
When trying to understand and treat asthma for those in adulthood, these results should be 
taken into consideration, and behavioral health factors must be assessed. Being able to 
identify behavioral health factors like smoking or environmental exposures can help to aid 
in the treatment of asthma.  
When looking at gender, there is a clear and definitive takeaway. Males are at an 
increased risk of needing SABA inhalers, and that risk increases as the number of SABA 
inhaler increases. The difference between the two genders is significant, with a 21% 
relative increase in >3 SABAs, a 25% relative increase in >6 SABAs, and a 30% relative 
increase in >12 SABAs. Males appear to be at an increased risk of asthma in this 
population, and the data shows they are also at an increased risk of needing SABA inhalers.  
The last component of objective 2 is the socioeconomic status. As discussed 
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previously, SIMD is the NHS breakdown of socioeconomic status. SIMD 1 represents the 
most deprived or the lowest socioeconomic status, and SIMD 5 represents the least 
deprived of the highest socioeconomic status. To make the results more evident, the relative 
risks and 95% confidence intervals were graphed as a forest plot. One can see that there is 
a linear difference in relative risk; going from the highest SES to the lowest SES, the 
relative risk for SABA inhalers increases. When comparing the three figures, one can see 
that as the number of inhalers increase, so does the spread between the groups. In the >12 
SABA figure, the most significant spread between relative risk in the SIMD groups. Those 
in the lower SIMD groups were assumed to have the least controlled asthma, and the 
graphs/data support this assumption. This represents some information that can help 
identify those at the highest risk, so that catered, and individually focused plans can be 
initiated by providers to try and lessen the burden that coincides with SES. When thinking 
about reasons for these discrepancies, environmental exposures, and behavioral health 
factors such as smoking emerge as potential culprits. Understanding likely socioeconomic 
differences can help healthcare and public health workers to more easily identify those at 
risk so that campaigns can be developed to limit the differences in exposure while also 
allowing tighter monitoring with medical therapy. Practitioners in Scotland should be alert 
to risk factors that their patients may have in relation to their SES. 
For objective 3, changes in the SIGN/BTS guidelines were investigated, and data 
was analyzed to ascertain how they may have changed prescribing habits. The two first-
line therapy medications of SABA and ICS were investigated. The significant changes in 
the guidelines have been the increasing priority of adding on ICSs and adding them to first-
line therapy options. Previously ICS were down the stepwise guidelines path, reserved for 
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those not controlled by SABAs. It is assumed that as the number of SABA inhaler claims 
increases, so too will the need for ICS. If patients do not have controlled asthma, then they 
should be on an ICS. When thinking about how ICS medications work, if a patient is on an 
ICS medication, they should receive one inhaler every month. This means that in a calendar 
year, they should have 12 claims for ICS medications. As the number of SABA 
medications increase, it is hypothesized that asthma is less controlled. So those receiving 
>12 SABAs should have ICS claims, and they should have ≥12 ICS claims. The ICS and 
SABA co-prescribing data were compared between the years to see how the guidelines 
might have influenced prescribing. When looking at the data, prescribing of ICSs has 
changed little. In the >3 SABA group, the prescribing of any ICS occurred in 77% in 2014 
and increased to 79% in 2018, a relative risk increase of 2.07%. In this group, there was a 
decrease in those receiving ≥12 ICS inhalers from 15.88% to 15.48%. In the >6 SABA 
group, there was an increase in those having any ICS claims from 84.88% to 86.09%. There 
was also a decrease in those receiving ≥12 ICS medications, moving from 25.64% to 
24.86%. In the last group, those receiving >12 SABAs, there was an increase in those 
receiving any ICS from 87.96% to 89.08%. This change resulted in only a 1.27% relative 
risk increase between the years. This group was the only group that had an increase in those 
receiving ≥12 ICS inhalers. But this was only a 0.64% relative increase between the years. 
It is more difficult to take away much information from the >3 or >6 SABAs groups due 
to the uncertainty of determining asthma control and uncertainty of the timing of the paid 
claims in the year. But when looking at the >12 SABA group, it is a bit easier to make 
assumptions about asthma control. In those receiving >12 SABAs, it is a clear indication 
for an ICS medication. One would expect that if they need that many reliever medications 
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that they would get at least one preventer medication. While this number has increased, it 
still is not at 100%. There remains 11% of the population that receives >12 SABAs that do 
not have adequate therapy based upon the SIGN/BTS guidelines. This equates to 1,667 
patients that are not receiving adequate goal-directed medical therapy and are therefore at-
risk for poor outcomes. For those receiving >12 SABAs and having claims for an ICS, the 
rates of those receiving ≥12 ICSs are lower than anticipated. Only 41.39% had received 
≥12 ICSs in 2018; a number only slightly increased from 2014 at 41.13%. This results in 
7,968 patients that are not receiving an adequate number of ICS inhalers per year. This 
number could represent poor compliance with ICS medications for those receiving >12 
SABAs. It is clear that ICS medications have numerous side effects [27]; this represents a 
potential reason for patients to stop taking them. If this does accurately represent a picture 
of poor compliance for ICS medications, then this is a clear area where healthcare providers 
and public health workers can make a difference. Poor adherence presents an opportunity 
to develop campaigns aimed at either the patients with asthma or the providers to address 
concerns of ICSs directly. These campaigns could ultimately allow higher compliance and 
better outcomes. If this is an issue with prescribing, then awareness campaigns can be 
created to target prescribers and the areas with poor co-prescribing. 
Limitations 
Limitations of this study include the lack of diagnosis codes. Without the diagnosis 
codes, the population had to be assumed to have asthma. This assumption overestimated 
those with asthma. It also forced the creation of age strata in which populations at-risk may 
have been suppressed. The age groups 40 and greater could represent additional data that 
could help show how guideline changes, studies, and NTI influenced prescribing. Data 
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analysis was limited to relative risk. Other statistical tests could be used with this data, and 
alternative study design could be made to give more definitive results and show new 
results. This data does not consider adherence. Without adherence, assumptions must be 
made about prescribing. If it turns out adherence is an issue, then the focus could shift to 
addressing poor adherence as opposed to influencing prescribing. The last perceived 
limitation is the lack of outcome measures, including hospitalization records or cost-saving 
measures. Hospitalizations represent a clinical and cost measure. Seeing the demographics 
of those needing hospitalization for asthma could either bolster data from this study, or it 
could bring additional information about who is at-risk for poor outcomes. 
Implications 
This study shows how asthma prescribing has changed over the years. It highlights 
areas were good progress has been made and shows areas where there remains room for 
improvement. Since the NRAD, there have been changes to try and influence outcomes. 
Seeing the data change and looking in-depth in the most recent full year of data gives an 
understanding of how these changes have influenced outcomes. It appears that more 
considerable attention has been focused on those with a higher risk of poor outcomes. More 
studies will be needed to investigate those below the far extreme category of this study. 
Still, there remain 15,263 patients at risk for poor outcomes due to excessive SABA use, 
1,667 patients not on goal-directed medical therapy with ICS medications, and 7,968 
patients were not receiving adequate amounts of ICS inhalers. This highlights areas that 
are still in need of improvement. When looking at the demographical analysis, this 
represents excellent insight to those at-risk for poor outcomes. The demographical analysis 
can be used to initiate more studies in these demographics to confirm the results and 
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investigate reasons for the differences. It can also be used as a marker for patients that may 
be at higher risk so that public health officials and practitioners can implement strategies 
to curtail any burden associated with these demographics.  
The resources NHS Scotland have at their disposal and ability to analyze their full 
population allow better monitoring and implementation of public health measures. Data 
replicated on patients in the United States may not be able to encompass the entire 
demographics, environmental differences, and regional differences that coincide with the 
United States. But this study can highlight how the implementation of guidelines and public 
health measures like the NTI, can change prescribing habits. NTIs could ultimately be 
replicated in the United States to more easily compare data throughout the country. Another 
advantage of the publicly funded healthcare system is that there is no cost for prescriptions 
to the patients. This likely eliminates an area for medical access issues and removes a 
potential confounder for outcomes that can be apparent in the United States. This likely 
means more patients are on the medications that were prescribed to them. While this does 
not guarantee a patient takes the medications as prescribed to them, it likely means fewer 
hurdles for the patients and more compliance. Thus, more can be concluded about the 
changes in prescribing habits and how guidelines, public health initiatives, and research 
can influence prescribing habits. 
Conclusion 
There appears to be an over-reliance on reliever medications, with a deficit in 
preventer medication use. This finding has improved from previous years’ data but 
highlights areas with room for improvement. Certain groups of the Scotland population are 
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at increased risk for large numbers of SABA inhalers – males, low socioeconomic status, 
and the age band 30-39. Lastly, based on NRAD findings, there seems to remain a large 
population at risk for poor outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 34	
References 
   
[1] Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: A 
roadmap to asthma control. Eur Respir J. 2015; 46(3): 622-639. DOI: 
https://doi.org/10.1183/13993003.00853-2015 
[2] Global Initiative for Asthma. Global Strategy for Asthma Management and 
Prevention, 2019. Available from: www.ginasthma.org  
[3] ’Byrne PM, Pedersen S, Schatz M, et al. The poorly explored impact of uncontrolled 
asthma. Chest. 2013;143(2):511–523. doi:10.1378/chest.12-0412 
[4] Nunes C, Pereira AM, Morais-Almeida M. 2017. Asthma costs and social 
impact. Asthma Res Pract. 3:1–11. 
[5] Masoli M, Fabian D, Holt S, et al. Global Initiative for Asthma (GINA) Program. The 
global burden of asthma: executive summary of the GINA Dissemination Committee 
report. Allergy 2004;59:469-78. http://www.ncbi.nlm.nih.gov/pubmed/15080825 
[6] To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings 
from the cross-sectional world health survey. BMC Public Health 2012; 12:204  
[7] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 
causes of death for 20 age grous in 1990 and 2010: a systematic analysis for the Global 
Burden of Disease Study 2010. Lancet 2013; 380: 2095-2128. 
[8] Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 
sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global 
Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196. 
	 35	
[9] Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. 
Global strategy for asthma management and prevention: GINA executive summary. Eur 
Respir J. 2008 Jan. 31(1):143-78. 
[10] Asthma UK. Number of people treated for asthma in the United Kingdom. 2013. 
www.asthma.org.uk/asthma-facts-and-statistics  
[11] Press release: UK asthma death rates among worst in Europe. (2018, May). Asthma 
UK. Retrieved February 24, 2020, from 
https://www.asthma.org.uk/about/media/news/press-release-uk-asthma-death-rates-
among-worst-in-europe/  
[12] Royal College of Physicians. Why Asthma Still Kills: the National Review of 
Asthma Deaths (NRAD) Confidential Enquiry Report. London, RCP, 
2014. www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf  
[13] Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing 
asthma without a preventer: urgent healthcare, poor asthma control and over-the- counter 
reliever use in a cross-sectional population survey. BMJ Open. 2017. https://doi-
org.ezproxy.uky.edu/10.1136/bmjopen-2017-016688. 
[14] National Therapeutic Indicators. ISD Scotland. https://www.isdscotland.org/Health-
Topics/Prescribing-and-Medicines/Publications/2019-07-16/visualisation.asp 
[15] MacBride-Stewart S, Hurding S, et al. National Therapeutic Indicators 2018. NHS 
Scotland. https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/08/National-
Therapeutic-Indicators-Report-2018-19-Version-1.0.pdf 
[16] Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky, PM. SMART Study 
Group. The salmeterol multicenter asthma research trial: a comparison of usual 
	 36	
pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 
2006;129(1):15-26 
[17] Dissanayake S.B. Safety of beta2-agonists in asthma: Linking mechanisms, meta-
analyses and regulatory practice. AAPS J. 2015;17:754–757. doi: 10.1208/s12248-015-
9734-8. 
[18] Kristensen N, Nymann C, Konradsen H. Implementing research results in clinical 
practice- the experiences of healthcare professionals. BMC Health Serv Res. 2016;16:48. 
doi: 10.1186/s12913-016-1292-y. 
[19] Gandhi, P.K., Kenzik, K.M., Thompson, L.A. et al. Exploring factors influencing 
asthma control and asthma-specific health-related quality of life among children. Respir 
Res 14, 26 (2013). https://doi.org/10.1186/1465-9921-14-26 
[20] Marjolein Engelkes, Hettie M. Janssens, Johan C. de Jongste, et al. Medication 
adherence and the risk of severe asthma exacerbations: a systematic review. European 
Respiratory Journal 2015 45: 396-407; DOI: 10.1183/09031936.00075614 
[21] Murphy Anna. How to help patients optimize their inhaler technique. The 
Pharmaceutical Journal. 2016 JUL 27. https://www.pharmaceutical-
journal.com/learning/learning-article/how-to-help-patients-optimise-their-inhaler-
technique/20201442.article 
[22] Erick Forno, M.D., M.P.H. and Juan C. Celedón, M.D., Dr.P.H. Health Disparities in 
Asthma. American Journal of Respiratory and Critical Care Medicine. Am J Respir Crit 
Care Med. 2012 May 15; 185(10): 1033–1035. Published online 2012 May 15. doi: 
10.1164/rccm.201202-0350ED 
	 37	
[23] Chronic obstructive pulmonary disease (COPD). World Health Organization. 
December 2017. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-
pulmonary-disease-(copd)  
[24] British Thoracic Society and Scottish Intercollegiate Guidelines Network. British 
guideline on the management of asthma. SIGN 158, updated 2019. Available at: 
www.sign.ac.uk/assets/sign158.pdf 
[25] Cates CJ, et al. Safety of regular formoterol or salmeterol in adults with asthma: an 
overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;(2):CD010314. 
[26] N.C. Thomson, R. Chaudhuri, E. Livingston. Asthma and cigarette smoking. 
European Respiratory Journal 2004 24: 822-833; DOI: 10.1183/09031936.04.00039004 
[27] Cooper, V., Metcalf, L., Versnel, J., Upton, J., Walker, S., & Horne, R. (2015). 
Patient-reported side effects, concerns and adherence to corticosteroid treatment for 
asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, 
cross-sectional study. NPJ primary care respiratory medicine, 25, 15026. 
https://doi.org/10.1038/npjpcrm.2015.26 
[28] British Thoracic Society and Scottish Intercollegiate Guidelines Network. British 
guideline on the management of asthma. SIGN 141, updated 2014. Available at: 
https://www.asthma.org.uk/bf7dd849/globalassets/campaigns/healthcare-improvement-
scotland.pdf 
[29] British Thoracic Society and Scottish Intercollegiate Guidelines Network. British 
guideline on the management of asthma. SIGN 153, updated 2016. Available at: 
https://www.brit-thoracic.org.uk/document-library/guidelines/asthma/btssign-asthma-
guideline-2016/  
	 38	
Appendix 
Figure 1 – 2014 SIGN/BTS asthma guidelines 
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Figure 2 – 2016 SIGN/BTS asthma guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: [29] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
